These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 30148984)

  • 1. Therapeutics development for addiction: Orexin-1 receptor antagonists.
    Perrey DA; Zhang Y
    Brain Res; 2020 Mar; 1731():145922. PubMed ID: 30148984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?
    Khoo SY; Brown RM
    CNS Drugs; 2014 Aug; 28(8):713-30. PubMed ID: 24942635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orexin Receptor Antagonists: Historical Perspectives and Future Opportunities.
    Andrews SP; Aves SJ; Christopher JA; Nonoo R
    Curr Top Med Chem; 2016; 16(29):3438-3469. PubMed ID: 26416477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?".
    James MH; Aston-Jones G
    Brain Res; 2020 Mar; 1731():146665. PubMed ID: 31930996
    [No Abstract]   [Full Text] [Related]  

  • 5. The potential role of the orexin reward system in future treatments for opioid drug abuse.
    Zarrabian S; Riahi E; Karimi S; Razavi Y; Haghparast A
    Brain Res; 2020 Mar; 1731():146028. PubMed ID: 30476469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System.
    Fragale JE; James MH; Avila JA; Spaeth AM; Aurora RN; Langleben D; Aston-Jones G
    Front Neurol Neurosci; 2021; 45():117-127. PubMed ID: 34052815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.
    Han Y; Yuan K; Zheng Y; Lu L
    Neurosci Bull; 2020 Apr; 36(4):432-448. PubMed ID: 31782044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM-878.
    Maehara S; Yuge N; Higashi C; Ota T; Furukawa J; Takeuchi T
    Neuropsychopharmacol Rep; 2020 Jun; 40(2):182-189. PubMed ID: 32337858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orexin OX
    Jacobson LH; Chen S; Mir S; Hoyer D
    Curr Top Behav Neurosci; 2017; 33():105-136. PubMed ID: 27909987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective orexin receptor antagonists.
    Lebold TP; Bonaventure P; Shireman BT
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4761-9. PubMed ID: 23891187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders.
    Bonifazi A; Del Bello F; Giorgioni G; Piergentili A; Saab E; Botticelli L; Cifani C; Micioni Di Bonaventura E; Micioni Di Bonaventura MV; Quaglia W
    Med Res Rev; 2023 Sep; 43(5):1607-1667. PubMed ID: 37036052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.
    Perrey DA; German NA; Decker AM; Thorn D; Li JX; Gilmour BP; Thomas BF; Harris DL; Runyon SP; Zhang Y
    ACS Chem Neurosci; 2015 Apr; 6(4):599-614. PubMed ID: 25643283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
    Winrow CJ; Renger JJ
    Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of human Orexin-1 and -2 G-protein-coupled receptors with novel and published antagonists by modeling, molecular dynamics simulations, and site-directed mutagenesis.
    Heifetz A; Morris GB; Biggin PC; Barker O; Fryatt T; Bentley J; Hallett D; Manikowski D; Pal S; Reifegerste R; Slack M; Law R
    Biochemistry; 2012 Apr; 51(15):3178-97. PubMed ID: 22448975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleus incertus Orexin2 receptors mediate alcohol seeking in rats.
    Kastman HE; Blasiak A; Walker L; Siwiec M; Krstew EV; Gundlach AL; Lawrence AJ
    Neuropharmacology; 2016 Nov; 110(Pt A):82-91. PubMed ID: 27395787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements.
    Roecker AJ; Mercer SP; Bergman JM; Gilbert KF; Kuduk SD; Harrell CM; Garson SL; Fox SV; Gotter AL; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4992-4999. PubMed ID: 25613676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dual orexin receptor antagonist TCS1102 does not affect reinstatement of nicotine-seeking.
    Khoo SY; McNally GP; Clemens KJ
    PLoS One; 2017; 12(3):e0173967. PubMed ID: 28296947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine.
    Gentile TA; Simmons SJ; Watson MN; Connelly KL; Brailoiu E; Zhang Y; Muschamp JW
    Neuropsychopharmacology; 2018 Apr; 43(5):1001-1009. PubMed ID: 28741623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy.
    Summers CH; Yaeger JDW; Staton CD; Arendt DH; Summers TR
    Brain Res; 2020 Mar; 1731():146085. PubMed ID: 30590027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.